DE false 0001597553 0001597553 2024-06-10 2024-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 10, 2024

 

 

Sage Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   001-36544   27-4486580

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

215 First Street

Cambridge, MA

   02142
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (617) 299-8380

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   SAGE   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Sage Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2024. At the Annual Meeting, the Company’s stockholders approved the Sage Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), which had previously been adopted by the Company’s board of directors (the “Board”) subject to stockholder approval.

A description of the material terms and conditions of the 2024 Plan is contained on pages 36 to 46 of the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 24, 2024 (the “Definitive Proxy Statement”), and is incorporated herein by reference. This description of the 2024 Plan is qualified in its entirety by reference to the complete text of the 2024 Plan, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

As of April 16, 2024, the record date for the Annual Meeting, there were 60,182,031 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters at the Annual Meeting, which are described in detail in the Definitive Proxy Statement: (i) to elect two directors, Elizabeth Barrett and Geno Germano, as Class I directors of the Company to each serve for a three-year term expiring at the Company’s annual meeting of stockholders in 2027 and until her or his successor has been duly elected and qualified, subject to her or his earlier death, resignation or removal; (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; (iii) to hold a non-binding advisory vote to approve the compensation paid to the Company’s named executive officers; and (iv) to approve the 2024 Plan.

At the Annual Meeting, the Company’s stockholders voted on the following proposals:

 

1.

The following nominees were elected to the Company’s Board as Class I directors for terms expiring at the 2027 annual meeting of stockholders.

 

Class I Director Nominee    For      Withheld      Broker Non-
Votes		  

Elizabeth Barrett

      27,582,793        22,463,987        3,358,174  

Geno Germano

      26,917,776        23,129,004        3,358,174  

 

2.

The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified.

 

For

  

Against

  

Abstain

52,272,319   1,106,440   26,195

 

3.

A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

 

For

  

Against

  

Abstain

  

Broker Non-Votes

47,705,636   2,299,792   41,352   3,358,174

 

4.

The 2024 Plan was approved.

 

For

  

Against

  

Abstain

  

Broker Non-Votes

34,334,451   15,678,289   34,040   3,358,174

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

Item 9.01.

Financial Statements and Exhibits.

 

Exhibit
No.		    Description
99.1    Sage Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-36544), filed on April 24, 2024).
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 11, 2024     SAGE THERAPEUTICS, INC.
    By:  

/s/ Anne Marie Cook

      Anne Marie Cook
      Senior Vice President, General Counsel
v3.24.1.1.u2
Document and Entity Information
Jun. 10, 2024
Cover [Abstract]  
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0001597553
Document Type 8-K
Document Period End Date Jun. 10, 2024
Entity Registrant Name Sage Therapeutics, Inc.
Entity File Number 001-36544
Entity Tax Identification Number 27-4486580
Entity Address, Address Line One 215 First Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 299-8380
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol SAGE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Sage Therapeutics Charts.
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Sage Therapeutics Charts.